Co-Founder/CEO
Switch Therapeutics
Switch Therapeutics develops precision neuroscience medicines using its proprietary Conditionally Activated siRNA (CASi) platform. This technology combines features of ASOs and siRNAs into a single molecule for efficient self-delivery and potent knockdown. The CASi platform enables cell-selective targeting to improve therapeutic windows for treating central nervous system diseases.
- Biotechnology
Updated 2 days ago
Funding
Raised to date
$68MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+2Funding rounds are not available yet.
Founders
Product
Problem
Current RNA interference (RNAi) therapies lack precise targeting, leading to off-target effects and limiting their efficacy, especially in treating central nervous system (CNS) diseases. Effective delivery and cell-specific activation of RNAi molecules in the CNS remain significant challenges.
Solution
Switch Therapeutics is developing Conditionally Activated siRNA (CASi) therapies, a novel approach to targeted RNA interference. CASi molecules combine the advantageous properties of single and double-stranded RNA, enabling efficient self-delivery, uptake, and potent, durable knockdown of disease-related genes. The CASi platform offers the ability to target specific cell types and cell states within the CNS, improving therapeutic windows and opening new avenues for RNAi therapy. The modular sensor domain of CASi allows for the attachment of targeting and biodistribution ligands, further enhancing cell selectivity.
Target Audience
The primary target audience includes patients suffering from central nervous system (CNS) diseases with high unmet medical needs, as well as pharmaceutical companies seeking innovative genetic medicines for CNS disorders.
Features
- CASi molecules consist of a modular sensor domain and a siRNA payload domain.
- Sensor domain modularity allows for the attachment of targeting and biodistribution ligands.
- Enables cell-selective knockdown of targets by RNAi.
- Improves therapeutic windows for existing targets.
- Facilitates efficient self-delivery and uptake.
- Offers potent and durable knockdown.